{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:27:48Z","timestamp":1794547668506,"version":"4.9.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103861"],"award-info":[{"award-number":["82103861"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2024JJ5457"],"award-info":[{"award-number":["2024JJ5457"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.eclinm.2025.103478","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T08:40:11Z","timestamp":1756543211000},"page":"103478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Real-world effectiveness of initial antiviral regimens in children with chronic hepatitis B: an age-stratified cohort study"],"prefix":"10.1016","volume":"88","author":[{"given":"Sisi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingping","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiying","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1713-4120","authenticated-orcid":false,"given":"Songxu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.eclinm.2025.103478_bib1","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S2468-1253(22)00386-7","article-title":"Global reporting of progress towards elimination of hepatitis B and hepatitis C","volume":"8","author":"Cui","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103478_bib2","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S2468-1253(19)30042-1","article-title":"Hepatitis B virus infection in children and adolescents","volume":"4","author":"Indolfi","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103478_bib3","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","article-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study","volume":"8","author":"Razavi-Shearer","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2025.103478_bib4","article-title":"Management of chronic hepatitis B in children: an unresolved issue","author":"Corte","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103478_bib5","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103478_bib6","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103478_bib7","first-page":"1309","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (2022 version)(in Chinese)","volume":"30","year":"2022","journal-title":"Chin J Hepatol"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103478_bib8","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0016-5085(98)70318-X","article-title":"Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial","volume":"114","author":"Sokal","year":"1998","journal-title":"Gastroenterology"},{"issue":"22","key":"10.1016\/j.eclinm.2025.103478_bib9","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa012452","article-title":"Clinical trial of lamivudine in children with chronic hepatitis B","volume":"346","author":"Jonas","year":"2002","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103478_bib10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/hep.28015","article-title":"Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen\u2013positive chronic hepatitis B","volume":"63","author":"Jonas","year":"2016","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103478_bib11","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/hep.25818","article-title":"Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B","volume":"56","author":"Murray","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.eclinm.2025.103478_bib12","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/jvh.13598","article-title":"Long-term benefits of interferon-\u03b1 therapy in children with HBeAg-positive immune-active chronic hepatitis B","volume":"28","author":"Wang","year":"2021","journal-title":"J Viral Hepat"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103478_bib13","first-page":"214","article-title":"Efficiency and influencing factors of interferon therapy for 1-6 years old children with chronic hepatitis B (In Chinese)","volume":"27","author":"Pan","year":"2020","journal-title":"Int J Virol"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103478_bib14","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/MPG.0b013e31815604fb","article-title":"Liver histology of children with chronic hepatitis treated with interferon-alpha alone or in combination with lamivudine","volume":"45","author":"Kuloglu","year":"2007","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"13","key":"10.1016\/j.eclinm.2025.103478_bib15","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/hepr.13227","article-title":"Suppression of hepatitis B surface antigen production by combination therapy with nucleotide analogues and interferon in children with genotype C hepatitis B virus infection","volume":"48","author":"Tajiri","year":"2018","journal-title":"Hepatol Res"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103478_bib16","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/apt.17667","article-title":"Age at treatment initiation predicts response in children with chronic hepatitis B","volume":"58","author":"Wu","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103478_bib17","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s12072-023-10631-9","article-title":"Functional cure is associated with younger age in children undergoing antiviral treatment for active chronic hepatitis B","volume":"18","author":"Zhang","year":"2024","journal-title":"Hepatol Int"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103478_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2015","journal-title":"Hepatol Int"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103478_bib19","first-page":"888","article-title":"The guideline of prevention and treatment for chronic hepatitis B: a 2015 update (in Chinese)","volume":"23","year":"2015","journal-title":"Chin J Hepatol"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103478_bib20","first-page":"938","article-title":"The guidelines of prevention and treatment for chronic hepatitis B (2019 version) (in Chinese)","volume":"27","year":"2019","journal-title":"Chin J Hepatol"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103478_bib21","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0168-8278(17)31827-5","article-title":"Consensus on pegylated interferon alpha in treatment of chronic hepatitis B (In Chinese)","volume":"25","author":"Zhang","year":"2017","journal-title":"Chin J Hepatol"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103478_bib22","first-page":"435","article-title":"Research progress on clinical antiviral treatment of chronic hepatitis B in children (In Chinese)","volume":"32","year":"2024","journal-title":"Chin J Hepatol"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103478_bib23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.21037\/atm.2016.11.52","article-title":"Pediatric hepatitis B treatment","volume":"5","author":"Komatsu","year":"2017","journal-title":"J Thorac Dis"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103478_bib24","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jhep.2019.06.009","article-title":"Early initiation of antiviral therapy contributes to a rapid and significant loss of serum HBsAg in infantile-onset hepatitis B","volume":"71","author":"Zhu","year":"2019","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103478_bib25","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.clinthera.2017.07.015","article-title":"Comparison of the efficacy of tenofovir versus tenofovir plus entecavir in the treatment of chronic hepatitis B in patients with poor efficacy of entecavir: a systematic review and meta-analysis","volume":"39","author":"Chen","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.eclinm.2025.103478_bib26","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1186\/s12879-024-09723-0","article-title":"Functional cure induced by tenofovir alafenamide plus peginterferon-alpha-2b in young children with chronic hepatitis B: a case series study","volume":"24","author":"Zeng","year":"2024","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103478_bib27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12072-022-10415-7","article-title":"The effectiveness of combination therapy with interferon and nucleoside analogs in pediatric patients with chronic hepatitis B: a systematic review and meta-analysis","volume":"17","author":"Li","year":"2023","journal-title":"Hepatol Int"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103478_bib28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.14218\/JCTH.2021.00142","article-title":"Clinical predictors of functional cure in children 1\u20136 years-old with chronic hepatitis B","volume":"10","author":"Pan","year":"2022","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.eclinm.2025.103478_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.972687","article-title":"Hepatitis B virus DNA integration as a novel biomarker of hepatitis B virus-mediated pathogenetic properties and a barrier to the current strategies for hepatitis B virus cure","volume":"13","author":"Salpini","year":"2022","journal-title":"Front Microbiol"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103478_bib30","article-title":"Hepatitis B virus enhancer 1 activates preS 1 and preS 2 promoters of integrated HBV DNA impairing HBsAg secretion","volume":"6","author":"Gu","year":"2024","journal-title":"JHEP Rep"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103478_bib31","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/lt.20519","article-title":"Changes in liver volume from birth to adulthood: a meta-analysis","volume":"11","author":"Johnson","year":"2005","journal-title":"Liver Transpl"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103478_bib32","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/cyto.a.22716","article-title":"Age- and sex-related reference intervals of lymphocyte subsets in healthy ethnic H an C hinese children","volume":"87","author":"Jia","year":"2015","journal-title":"Cytometry A"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103478_bib33","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s12072-015-9671-8","article-title":"Interferon-\u03b1 plus ribavirin yields 98 % sustained virologic response in children aged 1\u20135 years with iatrogenic chronic hepatitis C","volume":"9","author":"Zhu","year":"2015","journal-title":"Hepatol Int"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025004110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025004110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:06:19Z","timestamp":1794546379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025004110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":33,"alternative-id":["S2589537025004110"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103478","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness of initial antiviral regimens in children with chronic hepatitis B: an age-stratified cohort study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103478","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103478"}}